1. Tolentino J, Schmidt S DSM 5 Criteria and Depression Severity: Implications for Clinical Practice. Front Psychiatry [INTERNET] 2018 Oct [cited 2022 May 20]
2. FDA drug label Remeron (mirtazapine tablets) approved 2007,2009 [cited 2022 May 20]
3. Karsten J, Hagenauw LA, Kamphuis J, Lancel M Low doses of mirtazapine or quetiapine for transient insomnia, a randomised, double-blind, cross-over, placebo-controlled trial. J. Psychopharmacol [INTERNET] 2017 Mar [cited 2022 May 20]
4. Tajti J, Almas J Effects of mirtazapine in patients with chronic tension-type headache [Literature Review]. PubMed, Neuropsychopharmacol Hung [INTERNET] 2011 Jun [cited 2022 May 20]
5. Ringeisen H, Casanueva C, Stambaugh L, Bose J, Hedden S DSM-5 Changes: Implications for Child Serious Emotional Disturbance. Center for Behavioral Health Statistics and Quality.(2016). 2014 National Survey on Drug Use and Health: (unpublished internaldocumentation). Substance Abuse and Mental Health ServicesAdministration, Rockville, MD. [INTERNET] [cited 2022 May 20]
6. Mirtazapine (Remeron) Information Sheet. NAMI [online] [cited 2022 May 20]
7. Leonard S, Karlamangla A Dose-dependent Sedating and Stimulating Effects of Mirtazapine. UCLA Healthcare [INTERNET] Vol. 19 2015 [cited 2022 May 20]
8. Abdulkader A, Voronovich Z, Carley J A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions. PMCID [INTERNET] 2013 Oct [cited 2022 May 20]
9. Pfeiffer C, LaMola S Zinc and Manganese in the Schizophrenias. Journal of Orthomolecular Medicine [INTERNET] 1st quarter 1999 [cited 2022 May 20]
10. FDA Label Remeron/mirtazapine [INTERNET] Revised 2016 [cited 2022 May 20]
11. Benazzi F. Mirtazapine withdrawal symptoms. Can J Psychiatry. 1998 Jun;43(5):525. PMID: 9653542. [cited 2022 May 20]
12. Jilani TN, Gibbons JR, Faizy RM, et al. Mirtazapine. [Updated 2021 Mar 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519059/ [cited 2022 May 20]
13. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010 Jan;24(1):35-53. doi: 10.2165/11319480-000000000-00000. PMID: 20030418. [cited 2022 May 20]
14. Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290. Published 2015 Oct 8. doi:10.7573/dic.212290 [cited 2022 May 20]
15. Berigan T, “Mirtazapine-Associated Withdrawal Symptoms – A Case Report.” Primary Care Companion to the Journal of Clinical Psychiatry 2001 [cited 2022 May 17]
16. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol. 1998;12(3):305-13. doi: 10.1177/026988119801200311. PMID: 10958258. [cited 2022 May 20]
17. Jilani TN, Gibbons JR, Faizy RM, et al. Mirtazapine. [Updated 2021 Mar 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519059/ [cited 2022 May 20]
18. Khanna R, Boozalis E, Belzberg M, Zampella JG, Kwatra SG. Mirtazapine for the Treatment of Chronic Pruritus. Medicines (Basel). 2019 Jul 6;6(3):73. doi: 10.3390/medicines6030073. PMID: 31284577; PMCID: PMC6789675. [cited 2022 May 20]
19. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60 Suppl 4:4-11; discussion 12-3. PMID: 10086478. [cited 2022 May 20]
20. Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Iwata R, Matsuoka H, Yanai K. Histamine H₁ receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers. Psychopharmacology (Berl). 2013 Nov;230(2):227-34. doi: 10.1007/s00213-013-3146-1. Epub 2013 Jun 1. PMID: 23728612. [cited 2022 May 20]
21. Haefely W. Benzodiazepine interactions with GABA receptors. Neurosci Lett. 1984 Jun 29;47(3):201-6. doi: 10.1016/0304-3940(84)90514-7. PMID: 6147796. [cited 2022 May 20]
22. Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15(5):PCC.13r01525. doi:10.4088/PCC.13r01525 [cited 2022 May 20]
23. Grosso G. Nutritional Psychiatry: How Diet Affects Brain through Gut Microbiota. Nutrients. 2021 Apr 14;13(4):1282. doi: 10.3390/nu13041282. PMID: 33919680; PMCID: PMC8070365. [cited 2022 May 20]
24. Orisakwe OE. The role of lead and cadmium in psychiatry. N Am J Med Sci. 2014 Aug;6(8):370-6. doi: 10.4103/1947-2714.139283. PMID: 25210669; PMCID: PMC4158644.[cited 2022 May 20]
25. Attademo L, Bernardini F, Garinella R, Compton MT. Environmental pollution and risk of psychotic disorders: A review of the science to date. Schizophr Res. 2017 Mar;181:55-59. doi: 10.1016/j.schres.2016.10.003. Epub 2016 Oct 6. PMID: 27720315. [cited 2022 May 20]
26. Newbury JB, Stewart R, Fisher HL, Beevers S, Dajnak D, Broadbent M, Pritchard M, Shiode N, Heslin M, Hammoud R, Hotopf M, Hatch SL, Mudway IS, Bakolis I. Association between air pollution exposure and mental health service use among individuals with first presentations of psychotic and mood disorders: retrospective cohort study. Br J Psychiatry. 2021 Dec;219(6):678-685. doi: 10.1192/bjp.2021.119. PMID: 35048872; PMCID: PMC8636613. [cited 2022 May 20]
27. Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. Geneva: World Health Organization; 2009. 4, Withdrawal Management. Available from: https://www.ncbi.nlm.nih.gov/books/NBK310652/[cited 2022 May 20]